{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001856725","name":"Rani Therapeutics Holdings, Inc.","summary":"Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing the RaniPill capsule, a drug-agnostic oral delivery platform designed to deliver biologics and drugs—including antibodies, proteins, peptides, and oligonucleotides—as an alternative to injectable administration. The company offers two configurations: RaniPill GO (up to 3 mg microtablet dose) and RaniPill HC (up to 200 µL liquid payload). Key pipeline candidates include RT-114 for obesity and RT-117 for hemophilia. No products are approved or generating commercial revenue.","people":[],"products":[{"name":"RaniPill GO","type":"platform","description":"Oral drug delivery capsule delivering up to 3 mg drug dose in microtablet form with high bioavailability; completed three Phase 1 clinical trials."},{"name":"RaniPill HC","type":"platform","description":"High-capacity oral drug delivery capsule enabling liquid drug payloads up to 200 µL with high bioavailability; in Phase 1 clinical trial."},{"name":"RT-114","type":"platform","description":"RaniPill HC capsule containing GLP-1/GLP-2 dual agonist PG-102 for obesity treatment; Phase 1 clinical trial initiated December 2025 in Australia."},{"name":"RT-117","type":"platform","description":"RaniPill HC capsule containing Chugai's antibody for hemophilia; subject to worldwide collaboration and license with Chugai Pharmaceutical."}],"partnerships":[{"partner_name":"Chugai Pharmaceutical Co., Ltd.","partnership_type":"licensing","description":"Collaboration and License Agreement to develop and commercialize RT-117 (RaniPill HC with Chugai's hemophilia antibody); $10M upfront, up to $175M in milestones plus royalties.","start_date":null},{"partner_name":"ProGen Co., Ltd.","partnership_type":"development","description":"Worldwide collaboration for RT-114; ProGen's GLP-1/GLP-2 dual agonist PG-102 is the drug substance used in the RaniPill capsule for obesity treatment.","start_date":null},{"partner_name":"Celltrion, Inc.","partnership_type":"licensing","description":"Grants Rani a license and drug supply of ustekinumab and adalimumab biosimilars for use in RaniPill capsule pipeline programs.","start_date":null}],"affiliations":[],"origin":{"leaf":"900e813b0d7e1196e6b8175bdfdd3d6c15e7784366ac54fe7852a174945c230d","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"9cbb5cdd927478d6577dd15cb9abea54e328e4e7f1d3793ffadaab0f6fa17f2f","parent":"2545578da539a7f41dd2cb880f4308664fef899545d74a8cac141613830ef26f","source":"0001193125-26-126417","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}